Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
paroxetine hydrochloride hemihydrate, Quantity: 14.25 mg (Equivalent: paroxetine, Qty 12.5 mg)
Aspen Pharmacare Australia Pty Ltd
paroxetine hydrochloride hemihydrate
Tablet, modified release
Excipient Ingredients: lactose monohydrate; hypromellose; povidone; silicon dioxide; magnesium stearate; glyceryl behenate; iron oxide yellow; methacrylic acid copolymer; purified talc; triethyl citrate; titanium dioxide; sunset yellow FCF; polysorbate 80; quinoline yellow; macrogol 400
Oral
7 tablets - sample pack, 30 tablets
(S4) Prescription Only Medicine
AROPAX CR is indicated for the treatment of major depressive disorder and panic disorder, social anxiety disorder/social phobia and treatment of premenstrual dysphoric disorder. AROPAX CR has not been evaluated beyond 12 weeks, 10 weeks, 12 weeks and 3 menstrual cycles in controlled clinical trails for the treatment of major depression, panic disorder, social anxiety disorder and premenstrual dysphoric disorder, respectively.
Visual Identification: Yellow, round, biconvex film-coated tablet with bevelled edges. One side engraved with "GSK", the other with "12.5"; Container Type: Blister Pack; Container Material: PVC/Al; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius
Licence status A
2004-05-27